TS-042858 — A biodegradable drug delivery system for the treatment of disease, especially ophthalmic diseases including age-related macular degeneration (AMD). The device will be injected and can control drug release for at least 6 months following the initial injection.
Retinal diseases can be extremely difficult to monitor once procedures have been initiated. AMD is the fourth most common causes of blindness and requires monthly injections to manage the effects of the disease and prevent permanent blindness. However, receiving recurrent injections can potentiall…
